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Abstract
An increasing number of malignancies has been shown to be initiated and propelled by small subpopulations of cancer
stem cells (CSC). However, whether tumor aggressiveness is driven by CSC and by what extent this property may be
relevant within the tumor mass is still unsettled. To address this issue, we isolated a rare tumor cell population on the basis
of its CD44
+CD24
2 phenotype from the human androgen-independent prostate carcinoma cell line DU145 and established
its CSC properties. The behavior of selected CSC was investigated with respect to the bulk DU145 cells. The injection of CSC
in nude mice generated highly vascularized tumors infiltrating the adjacent tissues, showing high density of
neuroendocrine cells and expressing low levels of E-cadherin and b-catenin as well as high levels of vimentin. On the
contrary, when a comparable number of unsorted DU145 cells were injected the resulting tumors were less aggressive. To
investigate the different features of tumors in vivo, the influence of differentiated tumor cells on CSC was examined in vitro
by growing CSC in the absence or presence of conditioned medium from DU145 cells. CSC grown in permissive conditions
differentiated into cell populations with features similar to those of cells held in aggressive tumors generated from CSC
injection. Differently, conditioned medium induced CSC to differentiate into a cell phenotype comparable to cells of scarcely
aggressive tumors originated from bulk DU145 cell injection. These findings show for the first time that CSC are able to
generate differentiated cells expressing either highly or scarcely aggressive phenotype, thus influencing prostate cancer
progression. The fate of CSC was determined by signals released from tumor environment. Moreover, using microarray
analysis we selected some molecules which could be involved in this cell-to-cell signaling, hypothesizing their potential
value for prognostic or therapeutic applications.
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Introduction
Prostatic adenocarcinoma (PCa) is a leading cause of death
among men in the United States and Western Europe [1]. Because
of its androgen-dependent growth, hormone ablation remains the
main treatment of metastatic disease. While initially effective, this
treatment is followed in a few years by tumor recurrence [2] in
which an androgen-independent neuroendocrine (NE) subpopu-
lation of cells is thought to play an important role [3,4]. NE cells
are quiescent, terminally differentiated cells characterized by
dendrite-like processes extending between adjacent cells and by
the expression of neuronal-like proteins such as CD56 and
chromogranin A (CGA) contained in dense cytoplasmic granules
[5]. Through the secretion of neuropeptides NE cells modulate the
activity of normal prostate epithelium but are also capable to
influence adjacent transformed epithelial cells via paracrine
signals, thus stimulating tumor growth and metastatic capacity
[5–7]. In fact, an increased NE cell population in PCa is thought
to be associated with a more aggressive disease, whereas a low
number of NE cells in tumor tissue have no specific prognostic
meaning [6,8,9]. Interestingly, both NE and secretory epithelial
lineage are derived from a common pluripotent prostate stem cell
[10].
A further basic mechanism involved in the progression of PCa is
decreased expression of E-cadherin, the main transmembrane
adhesion molecule responsible for cell-to-cell interactions and
tissue organization in epithelial cells [11,12]. Through the
cytoplasmic domain, it binds b-catenin, which influences cyto-
skeletal arrangement [13]. As a consequence, loss of E-cadherin
function or expression is considered a crucial event in the
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the acquisition of an invasive phenotype in tumor cells [14]. In
particular, in PCa, lower expression of E-cadherin was associated
with more advanced tumor stage and grade [15,16]. Poorly
differentiated prostate tumors also showed higher expression of
vimentin, a cytoskeletal component responsible for maintaining
cell integrity, and high levels of vimentin correlated with the
invasive capacity of prostate cancer cell lines, including DU145
[17].
Traditionally, tumors have been considered to be composed of
heterogeneous cells with comparable unlimited proliferative and
tumorigenic potential. However, it has recently been hypothesized
that only rare cells within the tumor, named cancer stem cells
(CSC), are able to proliferate extensively and are tumorigenic,
whereas the majority of cells in the tumor mass show a variable
degree of differentiation and undergo a limited number of
divisions. Their contribution to tumor growth and metastatization
is considered to be rather limited. Importantly, this model implies
the need for a new therapeutic approach specifically targeted
towards the CSC in the attempt to definitively eradicate the tumor
[18]. However, whether tumor aggressiveness is driven by CSC
and by what extent this property may be biologically relevant
within the naturally occurring tumor mass is still unsettled.
As the presence of CSC in PCa [19] and prostate cancer cell
lines [20] was recently demonstrated on the basis of the surface
antigenic profile CD44
+/a2b1
hi/CD133
+ and CD44
+CD24
2,
respectively, in the present study we aimed to evaluate the
contribution of CSC to tumor progression. We isolated
CD44
+CD24
2 stem-like cancer cells from the androgen-indepen-
dent prostate cancer cell line DU145 derived from a brain
metastasis of human PCa, showed their CSC properties, and
investigated their phenotype and behavior with respect to the bulk
DU145 cells. Importantly, in this model of prostate cancer we
observed that CSC were able to generate highly aggressive tumors
in NOD/SCID mice and that this potential was limited by the
presence of differentiated DU145 cells with the consequent growth
of less aggressive tumors. Consistently, by growing CSC in
conditioned medium from DU145 cells in vitro, we unveiled that
diffusible factors released from differentiated tumor cells were able
to restrain CSC from differentiating into cell populations showing
an aggressive phenotype and with features similar to those of cells
held in tumors generated in mice from the injection of CSC.
Finally, functional analysis of genes found differentially expressed
in CSC and DU145 cells by microarray analysis confirmed the
essential role of cell-to-cell signaling molecules to determine the
behavior of CSC. Further investigations performed also in other
models of prostate cancer might assign prognostic or therapeutic
value to this signature.
Results
Isolation and characterization of CSC from DU145
prostate cancer cells
DU145 cells were enriched by fluorescence-activated cell
sorting (FACS) for the population expressing CD44
+CD24
2 [20]
which represented about 10% of bulk DU145 cells (Figure 1A).
We tested the stem-like properties of selected cells to indisputably
describe them as prostate CSC. A very small percentage of
CD44
+CD24
2 isolated cells was able to generate non-adherent
spherical clusters, termed spheroids or prostaspheres, in serum-free
medium supplemented with EGF, bFGF and insulin (Serum
Replacement Medium, SRM). Spheroids grew very slowly,
reaching the size of about 300 mm within 6–8 weeks (Figure 1B).
As expected, spheroids were enriched for CD44
+CD24
2 cells, as
determined by both immunofluorescence (IF) staining (data not
shown) and quantitative real-time PCR (Q-PCR) analysis, with
comparable results. In fact, in spheroids CD44 mRNA was
expressed at levels similar to DU145 cells, whereas the expression
of CD24 was significantly lower (Figure 1C).
Spheroids contained long-term self-renewing cells, as demon-
strated by the ability of a fraction of cells from dissociated
spheroids to generate new prostaspheres lasted over 5 passages
(Figure 1D).
We observed that spheroid cells displayed differentiation
capacity. In fact, when removed of growth factors and exposed
to 10% FBS-containing medium, a significant fraction of spheroid
cells became adherent, grew as a flat monolayer and showed a
heterogeneous morphology highly similar to DU145 cells after 20
days (Figure 1E). In the early days of growth in these permissive
conditions, spheroid cells showed a doubling time of about 50 h
that progressively decreased up to the proliferation rate of DU145
cells, namely 30 h, starting from 15 days of culture (Figure 1F).
Moreover, to confirm the appearance of the phenotype of DU145
differentiated cancer cells we analyzed the expression of the
intermediate filament protein vimentin. In fact, vimentin expres-
sion has been reported to be modulated during cell maturation
according to the cell lineage [21] and was found highly expressed
in DU145 cell line [17]. Actually, after 20 days in FBS-
supplemented medium, vimentin-negative cells derived from
spheroids expressed vimentin at levels comparable to DU145 cells
(Figure 1G).
Finally, we determined the tumor-producing ability of spheroid
cells with respect to unsorted DU145 cells into immunodeficient
mice. The injection of 1 spheroid of 300 mm in diameter,
containing approximately 5,000 cells, resulted in tumors in 80%
of mice, whereas the injection of 5,000 bulk DU145 cells
generated tumors in 40% of animals (Figure 1H). Moreover, the
tumor latency was also shorter in the spheroid-injected mice than
in the mice injected with unsorted cells (37 and 54 days,
respectively). The injection of 3610
6 DU145 cells, which were
used as controls, generated tumors with the lowest latency in all
the mice. Consistent with a previous report [20], all together our
results indicate that CD44
+CD24
2 spheroid cells present key
biological properties of CSC since they showed capacity for self-
renewal, were able to differentiate into parental DU145 cells and
were more tumorigenic than bulk DU145 cells when the same
number of cells was injected in mice.
Heterogeneous composition of spheroids
Spheroids up to 300–400 mm in diameter showed a compact
architecture (Figure 2A) due to the presence of very tight cell-to-
cell contacts, as seen on Transmission Electron Microscopy
(TEM). High-power magnification showed multiple junctional
complexes formed by desmosomes and adherent junctions
(Figure 2B). Spheroid cells also presented nuclear pore complexes
organized in annulate lamellae (Figure 2C), which are considered
precursors in the assembly of the nuclear envelop. They are
typically present in embryonic and immature cells and disappear
during differentiation [22]. However, spheroids also hold differ-
entiated cells that, in these culture conditions selective for stem
cells, showed several levels of cell degradation. In particular,
characteristic cytoplasmic blebs were evident (Figure 2D), indicat-
ing that the degrading phase approached cell necrosis (Figure 2F),
while nuclei appeared mostly intact (Figure 2E). These damages
suggest the terminal destiny of differentiated cells.
Spheroids and DU145 cells were also evaluated for the
expression of markers of stem (E-cadherin and b-catenin [23–
25]) and differentiated cells (vimentin). Immunofluorescence
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cell populations, but at higher levels in spheroids (Figures 2G and
2H, respectively). Notably, in spheroid cells E-cadherin and b-
catenin staining was localized on the plasma membrane, whereas
in DU145 cells it was mainly cytoplasmic, indicating that
differentiated tumor cells were quite independent of cell-to-cell
interactions. The mature phenotype of DU145 cells was
accompanied by a high expression of vimentin, which, on the
contrary, was expressed only by rare cells in spheroids (Figure 2I).
Therefore, we can conclude that spheroids are enriched for CSC
but also held some damaged differentiated cells destined to
necrosis.
Figure 1. Sorting, culture and characterization of stem-like cells from DU145 cell line. (A) FACS analysis of CD44 and CD24 expression in
DU145 cells. (B) Culture of isolated CD44
+CD24
2 cells growing in SRM as nonadherent prostaspheres (56objective). (C) Q-PCR of CD44 and CD24
expression in spheroid and DU145 cells. Data are presented as mean 6 SEM from 3 experiments. *, p,0.05 vs DU145 cells. (D) Self-renewal capacity
of spheroids. Serum supplementation and the withdrawal of growth factors induce the growth of spheroid cells as adherent cells with morphology
(E), proliferation rate (F) and expression of vimentin (G) comparable to DU145 cells. Photographs of spheroid cells were taken under a phase contrast
microscope after 10 and 20 days of growth in FBS-containing medium (206). The representative western blots show the expression of vimentin and
b-actin in spheroid cells grown in FBS-supplemented medium with respect to control spheroids and DU145 cells. The histogram displays the
densitometric quantification of vimentin normalized to b-actin levels. Values are expressed as mean 6 SEM from 3 independent experiments. (H)
Tumor incidence and latency after injection of 1 spheroid, 5,000 or 3610
6 DU145 cells in NOD/SCID mice.
doi:10.1371/journal.pone.0031467.g001
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Comparing tumors generated in NOD/SCID mice after
injection of 1 spheroid (containing approximately 5,000 total cells,
considering both CSC and damaged differentiated cells) or 5,000
unsorted DU145 cells (which contain mainly differentiated cells and
a very small percentage of CSC), several macroscopic differences
were evident at the time of tumor excision. Tumors from spheroids
grew deeply at the site of injection, invaded adjacent tissues and
showed marked vascularization. Differently, tumors originating
from DU145 cell injection grew superficially and appeared well
delimited and mobile in relation to the surrounding tissues. Visible
vessels were rare or absent (data not shown).
These differences were confirmed by histological analysis.
Spheroid-derived tumors were composed of monomorphic cells
with a high nucleus/cytoplasm ratio and presented a marked
infiltrative growth characterized by bands invading the surround-
ing muscular and adipose tissues (Figure 3A, left panel). On the
contrary, tumors generated from unsorted DU145 cells were
composed of morphologically heterogeneous subpopulations of
cells and showed an expansive growth, compressing rather than
infiltrating the adjacent host tissues (Figure 3A, right panel).
Interestingly, highly invasive tumors showed lower expression of
E-cadherin and b-catenin and higher expression of vimentin when
compared to scarcely invasive tumors (Figure 3B). Notably, in each
Figure 2. Structure and composition of spheroids. (A) Phase contrast evaluation of spheroid structure (106). (B) TEM analysis showing
desmosomes and adherent junctions (top and bottom, respectively) as well as the annulate lamellae (C) in spheroid cells. (D) Phase contrast (206)o f
a fragment of spheroid surrounded by cells characterized by protruding blebs of empty cytoplasm, which present intact nuclei as shown by DAPI
staining (406, E). (F) Staining with trypan blue shows the presence of dead cells in spheroids (106). Immunofluorescence staining of a section of
spheroids and DU145 cells (original magnification 6200) showing the expression of E-cadherin (G), b-catenin (H) and vimentin (I).
doi:10.1371/journal.pone.0031467.g002
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31467Figure 3. Analysis of tumors generated in NOD/SCID mice. (A) Histological staining with H&E of tumors grown following the injection of 1
spheroid or 5,000 DU145 cells showing highly invasive (left panel) and scantly invasive (right) phenotype (56). Asterisks indicate the borders between
tumors and the surrounding tissues. (B) Representative western blots showing the expression of E-cadherin, b-catenin and vimentin in tumors. (C)
IHC staining with anti-mouse CD31 antibody highlighting higher vessel density in spheroid-derived tumors (indicated by asterisks, left panel)
compared to tumors from DU145 cells (right). (D) Q-PCR showing mouse CD31 expression in tumors. Mouse B2M was used as endogenous control.
Values are mean 6 SEM from 3 experiments. *, p,0.05 relative to tumors generated from spheroid. (E) IHC with anti-CD56 antibody showing higher
density of NE cells in tumors generated from spheroid than from DU145 cells (206). (F) Q-PCR displaying CGA mRNA level in tumors. Results are
expressed as ratios between the target gene and the endogenous control GAPDH and represent mean 6 SEM from 3 independent experiments. *,
p,0.05 with respect to tumors generated from spheroid. (G) A representative FACS analysis showing the presence of CD44
+CD24
2 cells in tumors
generated from the injection of 1 spheroid in mice. Tumors originating from the injection of 5,000 DU145 cells showed a comparable CD44
+CD24
2
cell population (data not shown).
doi:10.1371/journal.pone.0031467.g003
Tumor Environment Controls the Fate of CSC
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e31467tumor the pattern of expression of these 3 markers was opposite to
that of the cells which originated the tumor itself, namely CSC or
DU145 cells (Figures 2G–2H).
Tumors generated from spheroids showed also a significant
higher number of blood vessels (p,0.0001), as monitored by
staining with the endothelial cell marker CD31 (Figure 3C, left),
when compared to tumors originated from DU145 cells
(Figure 3C, right). These results were confirmed by the analysis
of CD31 mRNA expression level (Figure 3D) and indicate active
neoangiogenesis in tumors generated from spheroids. In addition,
immunohistochemical (IHC) analysis showed a higher number of
cells positive for CD56, a marker of NE cells, in more invasive
tumors than in less invasive tumors (Figure 3E). This observation
was confirmed by real-time PCR analysis of CGA, a further
marker of NE cells (Figure 3F). Furthermore, FACS analysis of
tumors excised and digested revealed that both types of neoplasia
contained a comparable CD44
+CD24
2 cell population
(Figure 3G). These findings provide evidence that CSC were able
to generate highly invasive tumors in nude mice. However,
injection of CSC with DU145 differentiated tumor cells (i.e.
injection of unsorted DU145 cells) resulted in the growth of tumors
of low degree of aggressiveness.
Effect of conditioned medium from DU145 cells on the
differentiation of CSC
In view of the above findings, we investigated the influence of
DU145 differentiated cells on selected CD44
+CD24
2 prostate
CSC in vitro. Dissected spheroids were grown in DMEM
supplemented with FBS (to simulate the injection of spheroids in
mice) or in DMEM supplemented with FBS in which DU145 cells
were previously grown for 3 days (conditioned medium (CM), to
simulate the injection of bulk DU145 cells in mice). In both culture
conditions, CSC contained in spheroids grew in monolayer, but
their proliferation was significantly reduced when they were
cultured for 20 days in CM (247%; Figure 4A). The inhibition of
spheroid proliferation was further enhanced by increasing the
concentration of CM (data not shown). Moreover, it appeared
very evident that cells grown in FBS-containing medium were
quite independent from cell-to-cell interactions as they grew
mainly singly or in little groups with irregular shape, and their
morphology and pattern of growth were similar to those of DU145
cells (Figure 4B, left panel). On the contrary, cells in CM were
tight each other and grew mainly as roundish islands (Figure 4B,
right panel). Interestingly, after 20 days and only in the plates
containing FBS-supplemented medium, we observed the appear-
ance of cells exhibiting the dendrite-like morphology typical of NE
cells (Figure 4B, left panel and Figure 4C). The identity of these
cells was confirmed by the evaluation of CD56 expression in the
cytoplasmic granules of NE cells (Figure 4C, right panel). The
analysis of the expression of markers of stem and differentiated
cells highlighted that after 20 days in FBS-containing medium,
cells displayed levels of E-cadherin, b-catenin and vimentin
comparable to those shown by DU145 cells (Figure 4D). On the
contrary, cells grown for 20 days in CM exhibited levels of
expression intermediate between those shown by control CSC and
DU145 cells but closer to the levels of CSC. In particular, a
reduction in the expression of E-cadherin and b-catenin and a
slight increase in the level of vimentin with respect to control
spheroids was evident (Figure 4D). It is of interest to note that both
the high expression of adhesion molecules and the low expression
of vimentin indicated strong cell-to-cell interactions and reduced
cell motility, respectively, which agreed well with the peculiar cell
growth as isles. These results indicate that CSC cultured in
permissive conditions were able to generate terminally differenti-
ated cells, namely DU145 and NE cells. However, diffusible
factors released from DU145 cells prevented the differentiation of
CSC.
Gene expression profile of CSC and DU145 cells
To investigate the cellular response involved in tumorigenesis
both at the level of gene expression and at the pre-mRNA splicing
level, we performed a whole genome, splicing-sensitive microarray
analysis of DU145 cells and their selected CSC. RNA samples
prepared from each cell population were hybridized to Human
Exon 1.0 ST Arrays, which allow the definition of both
transcription patterns (gene-level analysis) and alternative pre-
mRNA maturation events (exon-level analysis). Gene-level expres-
sion profiling was detected by linear model statistics using an
empirical Bayes method to moderate the standard errors. To
evaluate transcriptional modifications, we analyzed gene expres-
sion changes in spheroid CSC vs DU145 cells. To identify
differentially expressed genes, we applied an absolute log2-fold
change $+/21 and a P-value#0.05 as cutoffs. The complexity of
the data set was reduced by removing the non-significant probe
sets (those not expressed and those not changing). In this way,
more than 400 genes whose levels were significantly different in
CSC and DU145 cells were selected. A complete list of the
differentially expressed genes is found in Table S1.
Analysis of selected genes
The differentially expressed genes were analyzed for their
molecular and cellular functions and associated pathways using the
Ingenuity Pathways Analysis software (IPA 7.0, Ingenuity
Systems). The IPA analysis identified more than 70 functional
classes, and among them, we selected the 8 most consistent classes
found enriched within the set of differentially expressed genes (i.e.,
cancer, cellular movement, cellular growth and proliferation, cell
morphology, cell death, cellular development, cell cycle, cell-to-cell
signaling and interaction; Figure 5A) that were suited to
characterize CSC and DU145 cells. We combined the genes
from the 8 selected functional classes, detecting 22 common genes
still showing functional links. These were then separated according
to their cellular localization. Interestingly, further analysis of the
sub-selected genes showed that 17 out of 22 gene products were
localized on the plasma membrane or were secreted in the
extracellular space (Figure 5B), strengthening our above findings
showing the importance of the interactions between CSC and the
microenvironment. Although the selected genes encoded proteins
with a wide variety of functions, 4 main groups could be identified:
1) Pro-angiogenic factors angiopoietin 2 (ANGPT2), vascular
endothelial growth factor C (VEGFC) and cysteine-rich angio-
genic inducer 61 (CYR61) were found down-regulated in CSC
with respect to DU145 cells; 2) Genes coding for adhesion
molecules E-cadherin (CDH1), integrin beta 6 (ITGB6) and
junction plakoglobin (JUP) were expressed more in CSC in
agreement with the parallel down-regulation of caveolae protein
(CAV1); 3) Tumor suppressor genes lipocalin 2 (LCN2), dipeptidyl
peptidase-4 (DPP4), insulin-like growth factor binding protein 3
(IGFBP3), thioredoxin interacting protein (TXNIP) and Kruppel-
like factor 4 (KLF4) were up-regulated in CSC; 4) Diffusible
factors relevant in the maintenance of stem cell niche such as
epidermal growth factor (EGF), bone morphogenetic protein 4
(BMP4) and transforming growth factor beta 2 (TGFB2) were also
differently expressed in CSC and DU145 cells. Noteworthy, 19 out
of 22 genes that we identified were not previously described to be
abnormally expressed in prostate CSC. These data confirm that
interactions with the microenvironment have a crucial role in the
control of the phenotype of CSC and suggest a limited number of
Tumor Environment Controls the Fate of CSC
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investigated. Moreover, most of the 22 selected genes could be
novel markers of prostate CSC.
Validation of gene expression
To confirm the differences in gene expression found by
microarray analysis, Q-PCR was performed for 7 differentially
expressed genes (CDH1, CYR61, DPP4, IGFBP3, ITGB6, LCN2,
TGFB2). In all cases, the differences in the mRNA levels were
confirmed (Figure 5C).
Role of the pathway of E-cadherin in the differentiation
of CSC
Q-PCR analysis showed that mRNA expression of lipocalin 2
and E-cadherin followed a comparable trend in CSC, DU145 cells
and in CSC grown for 20 days in FBS-containing medium or in
CM. In particular, mRNA levels of both genes were very high in
CSC contained in spheroids, were reduced in CSC grown in CM
and were significantly lower and comparable in CSC grown in
FBS-medium and in DU145 cells (Figure 6). This trend was in
agreement with the modulation of b-catenin expression previously
observed in the same culture conditions (Figure 4D). Collectively,
these results indicate that the pathway of E-cadherin was
modulated during CSC differentiation.
Discussion
Tumorigenicity of prostate CSC
CD44
+CD24
2 cells isolated from DU145 prostate carcinoma
cell line using cell surface markers were able to grow as non-
adherent spheroids in serum-free medium supplemented with
specific growth factors. As a result of asymmetric stem cell division
spheroids were enriched in cancer stem cells (CSC), but also held a
percentage of differentiated cells approaching necrosis. It should
be noted that CSC were able to undergo asymmetric division also
in vivo because after injection in mice, they both produced
differentiated cells that constituted the bulk of the tumor and self-
renewed themselves as demonstrated by the presence of
CD44
+CD24
2 cells in all excised tumors.
A striking difference in tumorigenic capacity was shown by the
different incidence and latency of tumors originating from
spheroid CSC or DU145 cells injection, with the former cell
population being more tumorigenic. We suggest that the delay in
tumor formation after the injection of 5,000 DU145 cells could be
ascribed to the negligible number of CSC held in DU145 cells
injected compared to the enriched amount of CSC contained in
each spheroid. These findings and this suggestion were further
confirmed by the injection of 3610
6 DU145 cells, which held a
greater amount of CSC than 1 spheroid and generated tumors in
just 1 week.
Importantly, the further in vivo evaluation of the biological
behavior of CSC contained in spheroids revealed that the
injection of spheroids in nude mice generated highly aggressive
tumors that were able to infiltrate the adjacent tissues and showed
high density of NE cells and substantial vascularization, both of
which were established features associated with prostate tumor
progression [6,26]. Our findings are consistent with a previous
report which showed by histological analysis that purified CD44
+
PCa cells, which possess many features of CSC, generated more
invasive and metastatic tumors than the corresponding CD44
2
cells [25]. Interestingly, we observed that invasive tumors
generated from spheroid injection showed low levels of E-
cadherin and b-catenin, consistently with the prognostic value of
these indicators, which inversely correlated with PCa invasiveness
and survival [15,27]. In confirmation of these findings, scarcely
invasive tumors originating from the injection of 5,000 DU145
cells expressed high levels of E-cadherin and b-catenin, and the
injection of 3610
6 DU145 cells generated non-invasive capsu-
lated tumors expressing the highest levels of E-cadherin and b-
catenin (data not shown). In addition, more invasive tumors
generated from spheroids also showed higher levels of vimentin,
which correlated with poorly differentiated and metastatic PCa
[17]. These data provide novel interesting information about the
characteristics of the cells held in tumors originated in mice from
the injection of CSC and DU145 cells. In particular, it appeared
evident that the phenotype of CSC and DU145 cells was different
from that of the cells of the tumors that they generated which
showed an opposite pattern of expression of E-cadherin, b-
catenin and vimentin. To explain this apparent contradiction it is
important to consider the broad plasticity of CSC whose
differentiation capacity is influenced by environmental stimuli.
With this in mind, of particular interest is the observation that
tumors generated by the injection of spheroids were more
aggressive than those produced from DU145 cells, suggesting that
CSC had the potential to form very aggressive tumors only when
they were injected deprived of differentiated cells. On the
contrary, when CSC were injected together with differentiated
cells (i.e., injection of bulk DU145 cells), their potential was not
expressed, and the resulting tumors were less aggressive. We
underline that the different levels of aggressiveness of tumors were
independent of the number of CSC inoculated, as confirmed by
the injection of 3610
6 DU145 cells, which contained the highest
amount of CSC but generated non-invasive tumors. We rather
believe that higher or lower levels of tumor aggressiveness depend
on the absence or presence of DU145 cells together with CSC.
Although obtained in a single model of prostate cancer, these
findings provide important information indicating that CSC can
be controlled by environmental mechanisms that induce them to
differentiate into cells expressing a highly or scarcely aggressive
phenotype, thus determining tumor aggressiveness. These results
lead us to speculate whether conventional therapies aimed to
decrease the tumor mass indiscriminately may facilitate tumor
progression as a consequence of removal of the differentiated
tumor cell population.
Interactions between CSC and DU145 cells
In an attempt to explain the different features of tumors in vivo,
we explored the pathways underlying the interactions between
Figure 4. Effect of CM from DU145 cells on the phenotype of CSC. (A) The proliferation of CSC contained in spheroids grown in FBS-
containing medium or in CM from DU145 cells was evaluated at different times of culture. Data are shown as the mean 6 SEM from 3 experiments.
Asterisks indicate a significant inhibitory effect of CM with respect to FBS-medium (*, p,0.05). (B) Phase contrast (106) of cells after 20 days in FBS-
containing medium or in CM showing the different pattern of cell growth. In the left panel, the rectangle highlights the presence of NE cells. (C)
Phase contrast (left, 206) and IF staining (right, 406) of branched NE cells generated from CSC grown in FBS-medium. In particular, the right panel
shows the expression of CD56 in the cytoplasm and in the long cell processes. (D) Representative western blots showing the changes in the
expression of E-cadherin, b-catenin, and vimentin in spheroid CSC grown in the different culture conditions with respect to control spheroids and
DU145 cells. The expression levels of the 3 proteins were determined by densitometric analysis of the respective bands and normalized to b-actin
levels. Values reported in the histograms are mean 6 SEM from 3 independent experiments.
doi:10.1371/journal.pone.0031467.g004
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PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e31467prostate CSC and differentiated DU145 cells in vitro.A sp o i n t e d
out in Figure 7, we observed a striking parallelism between the
phenotypes of cells held in the 2 types of tumor generated in
mice and those of the CSC grown in the 2 different culture
conditions. In particular, molecular and cellular analyses
demonstrated that CSC grown in permissive conditions in vitro
underwent terminal differentiation producing cell populations
with features similar to those of cells held in aggressive tumors
generated from CSC injection in nude mice, namely NE cells
and cells independent of cell-to-cell contacts, which were
indistinguishable from DU145 cells. These findings further
confirm the stem-like features of CD44
+CD24
2 cells analyzed
in this study, since CSC differentiation was able to generate both
prostate lineages, NE cells and epithelial cells. Moreover, it is
interesting to note that because products released from NE cells
enhanced the invasive potential of DU145 cells [28], NE cells
could participate in the differentiation of CSC grown in FBS-
medium towards a more aggressive phenotype. On the contrary,
CSC grown in the presence of signals released from DU145 cells
seemed to undergo an incomplete or alternative differentiation
program resulting into a cell phenotype comparable to cells of
scarcely aggressive tumors originated from the injection of bulk
DU145 cells in mice. Therefore, our results provided evidence
that the fate of prostate CSC was significantly context-dependent
because the aggressive behavior of CSC was clearly controlled by
cell-to-cell contacts as well as by soluble factors released from
DU145 cells.
Potentially relevant molecules in mediating the
interactions between CSC and microenvironment
T h ei m p o r t a n c eo ft h ei n t e r a c t ions with the microenviron-
m e n tt od e t e r m i n et h ep h e n o t y p eo fp r o s t a t eC S Cw a s
confirmed by performing microarray and IPA analyses of
s p h e r o i dC S Ci nc o m p a r i s o nw i t ht o t a lD U 1 4 5c e l l s .I nt h i sw a y
22 genes particularly significant in the control of prostate CSC
functions were selected most of which coded for products
localized on the plasma membrane or secreted in the
extracellular space. Many of these 22 genes have a well known
role in PCa and were expressed in DU145 cells as expected in
tumor cells. Interestingly, these genes were always inversely
e x p r e s s e di nC S Ca n di nD U 1 4 5c e l l s .I np a r t i c u l a r ,A N G P T 2 ,
CYR61 and VEGFC are involved in angiogenesis and are up-
regulated in prostate cancer [29–31]. Other genes code for
molecules involved in cell-to-cell adhesion, such as E-cadherin
(CDH1), which is the main component of adherent junctions
and whose reduced expression correlates with highly invasive
PCa [11,15]. JUP is a component of desmosomes and is less
expressed in cancer with respect to normal prostate tissue [32].
ITGB6, which mediates the interactions between adjacent cells
and between cells and extracellular matrix, is down-regulated
during tumor progression [33]. CAV1 mediates the internali-
zation of CDH1 and is up-regulated in prostate tumors [34].
Other genes act as tumor suppressors, such as IGFBP3, which
inhibits prostate cancer growth through suppression of angio-
genesis [35], and LCN2, which increases the expression of E-
cadherin and suppresses cell invasiveness [36]. DPP4, KLF4
and TXNIP instead inhibit cell migration and invasion and
induce cell cycle arrest [37–39]. Some of the selected genes play
a relevant role in the maintenance of the stem cell niche. In
particular, EGF induces stem cell differentiation, whereas
B M P 4a n dT G F B 2i n d u c eq u i e s c e n c e[ 4 0 ] .T h e s ef i n d i n g s
suggest that further investigations of the selected genes might
allow to identify molecules that participate in determining the
fate of CSC. In this regard, our preliminary results highlighted
that the pathway of E-cadherin was clearly involved in the
differentiation of prostate CSC. Notably, this last observation
indicates that therapeutic manipulation of the adhesive interac-
tions of prostate CSC could play an important role in the
control of tumor progression.
Although some of the 22 selected genes have previously been
identified in stem cells isolated in several different systems, only
CDH1, KLF4 and ITGB6 have been correlated to the phenotype
of prostate CSC [19,23]. Therefore, in this study, we identified 19
potential novel markers associated with CD44
+CD24
2 prostate
CSC that could be investigated for prospective new therapeutic
applications after further evaluation in other experimental
models.
Conclusions
In the present study, we report for the first time that context-
specific signals released from tumor microenvironment can induce
CSC isolated from DU145 prostate carcinoma cell line to
differentiate into mature tumor cells expressing a highly or
Figure 6. Influence of culture conditions on the expression of
lipocalin-2 and E-cadherin in CSC. Q-PCR showing changes in
mRNA levels for lipocalin-2 and E-cadherin in DU145 cells, CSC
contained in control spheroids, and CSC grown for 20 days in FBS-
medium or CM from DU145 cells. Data represent mean 6 SEM from 3
individual experiments. Asterisks indicate a significant difference (*,
p,0.05).
doi:10.1371/journal.pone.0031467.g006
Figure 5. Analysis of CSC vs DU145 cells by microarray, IPA and Q-PCR analysis. (A) Selected 8 top biological functions found enriched
within the set of transcripts modulated in CSC with respect to total DU145 cells by microarray analysis. (B) The 22 deregulated genes, as determined
by IPA, are positioned in subcellular layouts, and relationships are marked by arrows: filled and dashed line arrows mark direct and indirect
interactions, respectively. Genes in red showed increased expression in CSC, while genes in green were down-regulated. (C) Differences in gene
expression determined by microarray analysis were confirmed by Q-PCR, choosing 7 representative genes among selected 22. Results are expressed
as ratio between each target gene and the endogenous control GAPDH. Expression in CSC was compared to what was observed in DU145 cells to
which a value equal to 1 was arbitrarily assigned. Values are mean 6 SEM from 3 experiments. *, p,0.05 relative to DU145 cells.
doi:10.1371/journal.pone.0031467.g005
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progression. These findings encourage the identification of soluble
factors present in the CM from DU145 cells that can be
responsible for the control of the fate of the prostate CSC. For
this purpose, the information gained by microarray analysis could
be useful because it suggests a limited set of genes, most of which
have never been considered before, potentially relevant in the
interactions between CSC and the tumor microenvironment.
Materials and Methods
Ethics statement
Mice were purchased from Harlan Laboratories (Udine, Italy)
and housed in the animal facility of the Regina Elena Cancer
Institute, where there is currently no active ethical committee for
animal research. Animals had ad libitum water and food and were
maintained in standard conditions according to institutional
guidelines under the control of the Italian Ministry of Health
(DL 116/92).
Cell cultures
DU145 cells (ATCC, HTB-81) were routinely cultured in
DMEM medium (Invitrogen, Carlsbad, CA) supplemented with
10% FBS (HyClone, South Logan, UT) and 1% antibiotics
(Sigma-Aldrich, Saint Louis, MO) in a humidified atmosphere at
37uC and 5% CO2.
Sorting of CD44
+CD24
2 cells and cultures of spheroids
DU145 cells were incubated with anti CD44-PE and anti
CD24-FITC antibodies (Invitrogen) on ice for 15 min, washed
and resuspended in FACS buffer (PBS plus 1.5% BSA and 5 mM
EDTA) and kept on ice until subsequent analysis on FACS
Vantage-DIVA flow cytometer (excitation 488 nm, 100 mW,
emission 530 nm BP (BrdU) and 610 nm LP (PI); Beckton
Dickinson, San Jose, CA). Selected cells were seeded in 100 mm
diameter plates at about 200,000 cells/dish in SRM consisting of
DMEM/F12 medium (Invitrogen) supplemented with 20 ng/ml
EGF, 10 ng/ml bFGF, 5 mg/ml insulin, 0.4% BSA and 1%
antibiotics (Sigma-Aldrich). To avoid cell damage by centrifuga-
tions, 1 ml of fresh medium was added weekly in the plates until
spheroids were generated. At that time, each spheroid was drawn
with a tip and transferred to a new plate.
Analysis of spheroid differentiation
Spheroids were mechanically fragmented and seeded in DMEM
supplemented with 10% FBS. At different time points, cells were
detached and counted using a Neubauer counting chamber.
Photographs of the cells were taken under a phase contrast
microscope (Leica Microsystems, Wetzlar, Germany).
Western Blot analysis
To analyze protein expression in DU145 cells, control spheroids
and spheroid cells grown in FBS-containing medium or CM,
according to the experimental design, cell lysates were prepared by
solubilizing cells in lysis buffer containing 20 mM Tris pH 8,
137 mM NaCl, 1% Nonidet P40, 10% glycerol, 10 mM EDTA
pH 8 and a proteinase inhibitor cocktail (Complete TM, Roche
Diagnostics GmbH Mannheim, Germany) for 20 min on ice. The
supernatants were collected after centrifugation at 13,000 rpm for
15 min at 4uC. For protein extraction from mice tumors, frozen
tissues were homogenized with an Ultra Turrax T 25 homogenizer
in lysis buffer (2% SDS, 5 mM EDTA) supplemented with
proteinase inhibitor cocktail. Homogenates were boiled for
10 min and clarified by centrifugation at 13,000 rpm for 15 min.
The BCA Protein Assay Kit (Pierce, Rockford, IL) was used to
measure protein concentration.Equal amounts of proteins (20 mgo f
cell lysates or 40 mg of tissue extracts) were subjected to 8% SDS-
PAGE and electrophoretically transferred to PVDF membranes.
Membranes were probed with monoclonal antibodies anti-E-
cadherin (BD Transduction Laboratories, New Jersey, NJ), anti-b-
catenin (BD), anti-vimentin (Santa Cruz Biotechnology, Santa
Cruz, CA) and anti-b-actin (Sigma-Aldrich) followed by incubation
inthe presenceof theappropriate secondary antibodyconjugated to
peroxidase (Bio-Rad, Hercules, CA). The signal was then detected
by an enhanced chemiluminescence detection system.
Transmission electron microscopy studies
Spheroids were fixed in 2.5% glutaraldehyde in phosphate
buffer and then processed for TEM analysis following standard
procedures [41].
Figure 7. Parallelism between the phenotype of cells held in tumors and of CSC grown in vitro. In particular, CSC grown in FBS-medium
aimed to reproduce the injection of 1 spheroid in mice, whereas CSC grown in CM from DU145 cells allowed us to simulate the injection of 5,000
unsorted DU145 cells.
doi:10.1371/journal.pone.0031467.g007
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Spheroids were moved in a plate containing 1:4 Trypan blue in
SRM for 4 h, placed in PBS and photographed at phase contrast.
Spheroid cells showing cytosolic blebs were spotted on a glass slide,
stained with DAPI and analyzed by fluorescence microscope.
Immunofluorescence
Ten spheroids were placed in a well of a vinyl multiwell plate
(Costar, Cambridge, MA). The culture medium was carefully
removed, and 100 ml of OCT compound (Tissue Tek, Sakura,
Zoeterwoude, NL) was layered on spheroid sediments, which were
snap frozen by contact with liquid nitrogen. After the removal of
the vinyl coat, the embedded spheroids were cut (4 mm) in a Leica
CM 1850 cryostat microtome. Following air drying, sections were
fixed in absolute acetone for 5 min. The same fixing procedure
was applied to 15,000 DU145 cells plated in an 8 well Tissue
Chamber Slide (Nunc, Naperville, IL) and allowed to grow for 1
day. Primary antibodies and secondary fluoresceine-labeled
antibodies that were employed for immunophenotyping were
used at optimal dilutions established on positive and negative
controls. Primary antibodies anti-E-cadherin, anti-b-catenin (BD
Transduction Laboratories) and anti-vimentin (Santa Cruz
Biotechnology) were used. Fluorescein-labeled goat anti rabbit
IgG antibodies were purchased from Cappel Lab (Cochranville,
PA), and fluorescein-labeled F(ab)2 rabbit anti mouse IgG were
obtained from Sigma-Aldrich. Stained cells were analyzed
employing a Leica DMIRE2 microscope equipped with a Leica
DFC 350FX camera and elaborated by a Leica FW4000
deconvolution software (Leica, Solms, Germany).
Immunofluorescence staining for CD56 was performed on
spheroid cells grown for 20 days in FBS-supplemented medium.
Cells were fixed in 4% paraformaldehyde and permeabilized with
0.2% Nonidet P40. Primary antibody anti-CD56 (Epitomics,
Burlingame, CA) and secondary fluoresceine-labeled antibody
(Alexa Fluor 488, Invitrogen) were used. Nuclei were stained with
Hoechst before analysis by fluorescence microscope.
Mouse xenograft studies
Male NOD/SCID mice (6–8 weeks old, weight 22–25 g) were
maintained for 2 weeks prior to each experiment. Before cell
injection, animals were randomly allocated to one of the
following groups: a) not injected, b) injected with 1 spheroid
containing approximately 5,000 cells, c) injected with 5,000
unsorted DU145 cells, and d) injected with 3610
6 unsorted
DU145 cells. Each group consisted of 10 animals. On ice, 125 ml
DU145 cell suspensions or 125 ml SRM containing 1 intact
spheroid were mixed with 75 ml matrigel. Mice were injected
subcutaneously in the flank and monitored thrice every week for
palpable tumor formation for a total of 100 days. Tumor size was
measured with caliper and area was assessed by using the values
of long axis and short axis. Once tumors reached an area
between 1.2 and 1.5 cm
2, mice were euthanized, and tumors
were excised.
Histological and immunohistochemical analysis
At sacrifice, a portion of tumor samples was fixed in 4%
paraformaldehyde, paraffin-embedded and routinely stained by
hematoxylin and eosin (H&E). CD56 immunohistochemical
staining was carried out on 2 mm thick paraffin-embedded
sections harvested on SuperFrost Plus slides (Menzel-Glaser,
Braunschweig, Germany). The deparafinized and rehydrated
sections were incubated with anti-CD56 primary antibody
(Novocastra, Newcastle upon Tyne, UK) followed by anti-mouse
biotinylated antibody and streptavidin-peroxidase complex
(LSAB 2 system HRP, DakoCytomation, Milan, Italy) and 3,39-
diaminobenzidine (DAB substrate chromogen, DakoCytomation)
was used as chromogen. To assess blood vessels density, 4 mm
acetone-fixed cryostat sections were stained with anti-mouse
CD31 monoclonal antibody kindly provided by Prof. A.
Mantovani (Humanitas Inst. Milan, Italy) and MOM immu-
noenzymatic detection system purchased from Vectastain Labor
(Burlingame, CA). Amino-ethyl carbazole was employed as
chromogenic substrate. Nuclei were detected by slightly counter-
stain with Mayer hematoxylin and slides mounted in aqueous
mounting medium (UCS Diagnostic, Rome, Italy). Vessels
density was assessed by counting CD31 positive structures in at
least 15 randomly selected microscopic fields at 6200 magnifi-
cation. All morphological analyses were performed by two
independent investigators.
FACS analysis of tumors
Tumors excised from mice were collected in DMEM containing
FBS and immediately processed. Tumors generated from spheroid
injection needed an accurate removal of the adjacent murine
tissues. Neoplastic tissues were dissociated mechanically and
enzimatically using 2 mg/ml collagenase (Sigma-Aldrich) at
37uC for 90 min and sieved through 40 mm cell strainers. The
cells were then resuspended in FACS buffer and incubated with
anti CD44-PE and anti CD24-FITC antibodies for FACS analysis,
as previously described.
Conditioned medium experiments
DU145 cells were plated in 100 mm tissue culture dishes in
10 ml DMEM medium supplemented with FBS and grown for 3
days until subconfluence. The third day cells were harvested and
plated again at the starting density in fresh medium for another 3
days, whereas the medium removed from the plates was used as
CM from DU145 cells after being centrifuged at 1,000 rpm for
5 min and filtered through a 0.2 mm filter. This protocol was
repeated for the duration of the experiment (20 days). In parallel, 4
spheroids were fragmented and cultured in CM or in DMEM
containing FBS. The 2 culture media were replaced every 3 days
with fresh CM or FBS-supplemented medium up to 20 days. To
increase the concentration of soluble factors released from DU145
cells in CM a double number of DU145 cells were cultured in
10 ml FBS-containing medium for 3 days. As previously described,
every 3 days cells were harvested and plated again at the starting
density, whereas the collected medium was used as enriched CM
to grow CSC contained in spheroids for a total of 20 days. On
days 5, 10, 15 and 20, the proliferation of cells was measured with
a Neubauer counting chamber. The cell culture morphology was
observed under an optical microscope.
RNA extraction
Total RNA was extracted from DU145 cells, control spheroids
(groups of at least 30 spheroids of 400 mm in diameter or smaller)
and spheroid cells grown in FBS-containing medium or in CM,
according to the experimental design, through RNeasy Plus Micro
Kit (Qiagen, Valencia, CA). For RNA extraction from mice
tumors, frozen tissues were homogenized with an Ultra Turrax T
25 homogenizer in Trizol reagent (Invitrogen) and processed
according to the manufacturer’s instructions. RNA quantity and
purity were assessed using a NanoDropH instrument (Thermo
Fisher Scientific Inc., Wilmington, DE). Total RNA integrity was
assessed by Experion RNA Standard Sense kit (BioRad), and the
RNA Integrity Number was calculated.
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Each condition was replicated 3 times. After extraction from
spheroids and DU145 cells and quality checks, 70 ng of total RNA
was retrotranscribed to cDNA by using the Applause
TM WT-Amp
Plus ST RNA Amplification Systems (NuGEN Technologies, San
Carlos, CA). Five microliters of cDNA was fragmented and biotin-
labeled by the Encore
TM Biotin Module (NuGEN Technologies)
following the procedure described by the manufacturer. The
resulting biotin-labeled library was hybridized on GeneChipH
Exon 1.0 ST human microarrays (Affymetrix, Santa Clara, CA).
The CEL files resulting from the hybridization were analyzed
using oneChannelGUI 1.6.5 [42]. Gene-level calculations were
performed by Robust Multichip Average [43] and normalization
by quantile sketch [44]. To assess differential expression at the
gene-level, we used an empirical Bayes method [45] together with
a false discovery rate (FDR) correction of the p-value [46]. Thus,
the list of differentially expressed genes was generated using an
FDR#0.05 together with an absolute log2-(fold-change) threshold
of 1. Differential expression was detected by linear model statistics.
This method is based on the fitting of a linear model to estimate
the variability in the data. In the case of one-channel microarray
data, this approach is the same as the analysis of variance except
that a model is fitted for every gene. For the detection of the
differential expression, an empirical Bayes method is used to
moderate the standard errors. The use of moderated statistics for
the detection of differential expression is especially useful in cases
of experiments with a small number of replicates.
The data discussed in this publication have been deposited in
the NCBI Gene Expression Omnibus [47] and are accessible
through GEO Series accession number GSE28313.
cDNA synthesis and quantitative PCR
RNA was reverse-transcribed to single strand cDNA using
random primers and Superscript II (Invitrogen). The ABI Prism
7000 Sequence Detection System and all reagents for Q-PCR
were purchased from Applied Biosystems (Foster City, CA).
Primers and probes for human CD44, CD24, CGA, CDH1,
CYR61, DPP4, IGFBP3, ITGB6, LCN2, TGFB2 and mouse
CD31, and for the endogenous reference genes human glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) and mouse b2-
microglobulin (B2M) were purchased as TaqMan Gene Expres-
sion Assays. cDNA template was amplified in a reaction mixture
containing TaqMan Universal PCR master mix and primers/
probe mixture according to the manufacturer’s default cycling
conditions. For each amplification reaction, a standard curve was
generated using serial dilutions (200, 40, 8, 1.6, 0.32 ng) of reverse-
transcribed RNA extracted from DU145 cells or tumors generated
from spheroid injection, according to the experimental design, and
run concurrently with the test samples. All amplification reactions
were performed in triplicate. Target gene expression was
normalized to GAPDH or to B2M to correct for differences in
the quantity of cDNA used for the amplification reactions.
Statistical analysis
Mean values 6 SEM from 3 independent experiments are
shown. Statistical analysis was performed using the unpaired
Student’s t-test. P values of ,0.05 were considered significant.
Supporting Information
Table S1 List of differentially expressed genes in CSC
and DU145 cells obtained by microarray analysis. Fold
change represent the differential expression level of each gene in
spheroid CSC with respect to DU145 cells. Genes listed in red are
over-expressed in CSC, whereas genes showed in green are less
expressed.
(XLS)
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